. . . . . . . . . . "# Lindsay SE, Gudelsky GA, Heaton PC: Use of modafinil for the treatment of attention deficit/hyperactivity disorder. Ann Pharmacother. 2006 Oct;40(10):1829-33. Epub 2006 Sep 5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16954326 # Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A: Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett. 2003 Mar 20;339(2):143-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12614915"@en . . "investigational"@en . . . . . . . . . . . . . . . . . . . . "The major route of elimination is metabolism (~90%), primarily by the liver, with subsequent renal elimination of the metabolites."@en . "23-215 hours"@en . "Humans and other mammals"@en . . . . . . . . "Take without regard to meals."@en . . . . . "60%"@en . "\"DrugSyn.org\":http://www.drugsyn.org/Modafinil.htm"@en . . "Modafinil"@en . . . . "Modafinilum"@en . "Modafinil"@en . "approved"@en . . . . "Rapid following oral administration."@en . . "Modafinilo"@en . "68693-11-8"@en . . "To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy."@en . . "* 0.9 L/kg"@en . . . "Provigil"@en . . . . . . . . "Moderateafinil"@en . . . "Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA."@en . . . " "@en . . . . "The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. Modafinil is thought to have less potential for abuse than other stimulants due to the absence of any significant euphoric or pleasurable effects. It is possible that modafinil acts by a synergistic combination of mechanisms including direct inhibition of dopamine reuptake, indirect inhibition of noradrenalin reuptake in the VLPO and orexin activation. Modafinil has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors."@en . . . . . . . . . .